DNM2-related intermediate Charcot-Marie-Tooth neuropathy

Common Name(s)

DNM2-related intermediate Charcot-Marie-Tooth neuropathy

Charcot-Marie-Tooth disease is a clinically and genetically heterogeneous disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Classification CMT neuropathy is subdivided into CMT1 (see {118200}) and CMT2 (see {118210}) types on the basis of electrophysiologic and neuropathologic criteria. CMT1, or hereditary motor and sensory neuropathy type I (HMSN I), is a demyelinating neuropathy, whereas CMT2, or HMSN II, is an axonal neuropathy. Most patients with CMT are classified as having CMT1 or CMT2 by use of a cut-off value of 38 m/s for the motor median nerve conduction velocity (NCV). However, in some families with CMT, patients have motor median NCVs ranging from 25 to 45 m/s. Families of this type were reported by {6:Salisachs (1974)} and {2:Davis et al. (1978)}. {2:Davis et al. (1978)} proposed that this form be designated 'intermediate' CMT. {1:Claeys et al. (2009)} stated that some CMT families may have an even broader range of NCV than 25 to 45 m/s, with the lowest levels around 25 and the highest levels within the normal range (50+ m/s). They also suggested that the term 'intermediate' should not be used to describe a single NCV value, but rather the CMT subtype at the level of the family (e.g., in families with a range or combinations of NCV values). Genetic Heterogeneity of Autosomal Dominant Intermediate CMT In addition to CMTDIB, which is caused by mutation in the DNM2 gene, other forms of dominant intermediate CMT include CMTDIC ({608323}), caused by mutation in the YARS gene ({603623}) on chromosome 1p35-p34l; CMTDID ({607791}), caused by mutation in the MPZ gene ({159440}) on chromosome 1q22; CMTDIE with focal segmental glomerulosclerosis (CMTDIE; {614455}), caused by mutation in the INF2 gene ({610982}) on chromosome 14q; and CMTDIF ({615185}), caused by mutation in the GNB4 gene ({610863}) on chromosome 3q26. CMTDIA ({606483}) has been mapped to chromosome 10q24.1-q25.1.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "DNM2-related intermediate Charcot-Marie-Tooth neuropathy" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "DNM2-related intermediate Charcot-Marie-Tooth neuropathy" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "DNM2-related intermediate Charcot-Marie-Tooth neuropathy" returned 0 free, full-text research articles on human participants.

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "DNM2-related intermediate Charcot-Marie-Tooth neuropathy" returned 0 free, full-text review articles on human participants.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.